GSK plc Circulates Shareholder Vote on Pfizer Consumer Health Joint Venture
GSK plc has issued a circular and notice of a general meeting to its shareholders, requesting a vote on a proposed joint venture with Pfizer Inc. The meeting will address the formation of a new entity for their consumer healthcare businesses.
GSK plc has formally notified its shareholders of an upcoming general meeting where a crucial vote will take place regarding the proposed formation of a joint venture with Pfizer Inc. The meeting is scheduled for May 8, 2019, in London.
The proposed transaction involves combining the consumer healthcare businesses of both GSK and Pfizer. The company has provided detailed documentation to shareholders, including a letter from the Chairman recommending a vote in favor of the resolution. Shareholders are advised to review all provided materials thoroughly.
The circular outlines the strategic rationale behind the proposed joint venture, emphasizing its potential impact on the future of GSK's consumer healthcare operations. It also includes important information on risk factors associated with the transaction and comprehensive instructions for shareholders on how to cast their vote, whether in person or by proxy.
The deadline for submitting proxy votes is May 3, 2019, with specific instructions for both ordinary shareholders and ADR holders. The company urges shareholders to participate in the voting process to decide on this significant business development.